Monograph Wealth Advisors’s Connect Biopharma Holdings CNTB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$26.5K Hold
11,130
﹤0.01% 142
2026
Q1
$29.2K Hold
11,130
﹤0.01% 143
2025
Q4
$31.4K Hold
11,130
﹤0.01% 135
2025
Q3
$16.8K Buy
+11,130
New +$19.7K ﹤0.01% 139

Other funds holding CNTB

Monograph Wealth Advisors's CNTB Position: Q2 2026 in Review

Monograph Wealth Advisors held its Connect Biopharma Holdings (CNTB) position steady in Q2 2026 at 11,130 shares worth $26.5K. The position accounts for ﹤0.01% of the portfolio, ranked #142.

Monograph Wealth Advisors first reported a position in CNTB in Q3 2025 and has held it in 4 quarters since. The position peaked at $31.4K in Q4 2025. 56 funds tracked by Wall St. Rank hold CNTB as of Q2 2026.

  • Monograph Wealth Advisors held 11,130 shares of Connect Biopharma Holdings worth $26.5K as of Q2 2026.
  • Monograph Wealth Advisors left its Connect Biopharma Holdings share count unchanged in Q2 2026.
  • Connect Biopharma Holdings made up ﹤0.01% of Monograph Wealth Advisors's portfolio in Q2 2026, its #142 holding.
  • Monograph Wealth Advisors first reported a position in Connect Biopharma Holdings in Q3 2025 and has held it in 4 quarters since.
  • Monograph Wealth Advisors's Connect Biopharma Holdings position peaked at $31.4K in Q4 2025.
  • 56 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2026.

Based on Monograph Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.